Silibinin - Rottapharm Madaus
Alternative Names: Legalon; Legalon SIL; silybin - Rottapharm MadausLatest Information Update: 15 Oct 2021
At a glance
- Originator Rottapharm Madaus
- Developer Rottapharm Madaus; University of Leipzig
- Class Antidotes; Antihyperlipidaemics; Antivirals; Chromans; Dioxins; Hepatoprotectants
- Mechanism of Action DNA-directed RNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Liver disorders; Poisoning
- Discontinued Hepatitis C
Most Recent Events
- 24 Oct 2018 Discontinued - Phase-II for Hepatitis C (Adjunctive treatment, Treatment-experienced) in Germany (IV)
- 04 Mar 2015 Rottapharm Madaus withdraws the phase II/III HEPASIL trial prior to enrolment for Hepatitis C (treatment-naive) in Egypt (NCT01871662)
- 19 Feb 2015 University of Leipzig completes a phase II trial in Hepatitis C (Adjunctive treatment, Treatment-experienced) in Germany (EudraCT2012-004442-15) before February 2015